89bio, Inc.
NASDAQ•ETNB
CEO: Mr. Rohan Palekar
板块: Healthcare
行业: Biotechnology
上市日期: 2019-11-11
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.
联系方式
市值
$2.20B
市盈率 (TTM)
-7.8
24.5
股息率
--
52周最高
$15.06
52周最低
$4.16
52周范围
排名70Top 99.2%
1.1
F-Score
改良版 Piotroski 分析
基于 7 年期基本面
疲弱 • 1.1 / 9 分
评分区间 (0-9)
8-9: 价值优异
6-7: 基本面强劲
4-5: 整体稳健
0-3: 表现疲弱
数据范围: 2019-2025
深度研究
财务数据
电话会议
财务报告
新闻
利润表
资产负债表
现金流量表
财务比率
变化率
利润表 | 过去12个月 |
|---|
无数据